Next-generation solution designed to simplify procedures and support long-term outcomes

Stryker (NYSE: SYK), a global leader in medical technologies, will launch its Incompass™ Total Ankle System at the 2025 American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Savannah, Georgia, September 10–13, 2025 (booth # 401). The FDA-cleared system is intended for patients with end-stage ankle arthritis and introduces an innovative implant with an enhanced instrument platform.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909873413/en/

Stryker's FDA-cleared Incompass Total Ankle System is intended for patients with end-stage ankle arthritis and introduces an innovative implant with an enhanced instrument platform.

“Incompass was developed with one goal in mind: to give surgeons more flexibility and confidence in the OR while improving outcomes for their patients,” said Adam Jacobs, vice president and general manager of Stryker’s Foot & Ankle business. “This advanced system has been fully reimagined by the insights of countless surgeons, engineers, and real-world use cases built on 20 years of experience. We’re proud to continue leading the way in total ankle innovation and help shape what’s next for ankle arthroplasty.”

Incompass provides a comprehensive approach to total ankle replacement. It was developed to mimic Stryker’s Infinity and Inbone with a similar implant profile, fixation and sulcus articulation. Leveraging these two legacy designs, Stryker created Incompass, aiming to advance clinical performance, address evolving surgeon needs and deliver meaningful value to hospitals and patients. Both legacy systems have documented five-year survivorship rates of 98% or higher.^1,2

The system offers intraoperative flexibility, enabling surgeons to adjust implant configurations in real time to support patient-specific needs. Incompass includes 3D-printed porous metal tibial and talar components engineered to promote early bony ingrowth, often as early as four weeks.³ By combining implant options and reducing instrumentation, the system helps reduce procedural complexity, enhance decision-making and lower sterilization demands.

The implants were designed using SOMA, Stryker’s Orthopedic Modeling and Analytics tool, which analyzed real patient anatomy from arthritic ankle CT scans in the Prophecy^® database. SOMA was used to study bone quality and optimize implant location.

Further insights were gained from more than 80,000 Prophecy scans⁴. The system’s instrumentation was refined with input from a global clinical advisory team of experienced foot and ankle surgeons and informed by more than 100,000 total ankle cases,⁴ reinforcing Stryker’s commitment to evidence-based design and long-term patient outcomes.

Visit Booth #401 at AOFAS 2025 to learn more.

About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

References:

1. Gagne OJ, Day J, Kim J, Caolo K, O’Malley MJ, Deland JT, Ellis SJ, Demetracopoulos CA. Midterm Survivorship of the INBONE II Total Ankle Arthroplasty. Foot & Ankle International. 2022 May;43(5):628–636. doi:10.1177/10711007211060047
2. Early experience and patient-reported outcomes of 503 Infinity total ankle arthroplasties: A Concise Follow Up Townshend et al., Oct 2023 | The Bone & Joint Journal | Vol. 103-B, No. 7
3. Data on file at Stryker. Claim based on data from rabbit femur model. It is unknown how these results compare with clinical results in humans.
4. Based on internal data.

Copyright © 2025 Stryker

Content ID: FA-INCO-PRESS-2253361

View source version on businesswire.com: https://www.businesswire.com/news/home/20250909873413/en/